Aastrom Biosciences Inc., of Ann Arbor, Mich., was granted U.S. Patent No. 6,667,034 B2 covering a method of bone marrow transplantation, often referred to as stem cell transplants, using cells produced with Aastrom's single-pass perfusion technology that enables the growth of normal human cells outside the body.

Advanced Viral Research Corp., of Yonkers, N.Y., was issued U.S. Patent No. 6,696,422 for the treatment of HIV infections with AVR118 as a combination therapy with other HIV drugs.

Antares Pharma Inc., of Exton, Pa., was awarded U.S. Patent No. 6,696,085 on the formulation technology associated with its Easy Tec fast-melt tablet technology.

Biolog Inc., of Hayward, Calif., received U.S. Patent No. 6,686,173 for comparative phenotypic analysis of two or more microorganisms using a variety of substrates within a microwell device.

Isotechnika Inc., of Edmonton, Alberta, was granted U.S. Patent No. 6,686,454 titled "Antibodies to Specific Regions of Cyclosporine-Related Compounds." The company also was granted a notice of allowance for its U.S. patent application titled "Deuterated Cyclosporine Analogues and Their Use as Immunomodulating Agents."

Locus Pharmaceuticals Inc., of Blue Bell, Pa., was issued a notice of allowance for a computational method for the design of new drugs, the first patent allowance for its core technology.

Metabolic Pharmaceuticals Ltd., of Victoria, Australia, was awarded a notice of allowance on its patent application related to its AOD9604 obesity compound and a range of similar compounds.

Medicure Inc., of Winnipeg, Manitoba, was issued U.S. Patent No. 6,667,356 covering methods of treating hypertension with MC-1 in combination with various classes of anti-hypertensive drugs. The company also received U.S. Patent No. 6,667,315 covering composition-of-matter claims and compound claims in a series of drugs for cardiovascular and related diseases.

Oncolytics Biotech Inc., of Calgary, Alberta, was awarded U.S. Patent No. 6,703,232 titled "Method of Producing Reovirus," claiming the production of reassorted reoviruses for the treatment of Ras-mediated tumors.

Peregrine Pharmaceuticals Inc., of Tustin, Calif., received U.S. Patent No. 6,703,020 covering the use of therapeutic agents that target vascular endothelial growth factor for the treatment of solid tumors. The company also received U.S. Patent No. 6,696,276 titled "Vasopermeability-Enhancing Conjugates," covering its Vasopermeation Enhancement Agent technology.